Wird diese Nachricht nicht richtig dargestellt, klicken Sie bitte hier.
Deutsche Sarkom Stiftung
SPAGN Member groupsUnsubscribe newsletter • Contact
Dear SPAGN Members and Friends,

the path to a correct diagnosis for sarcoma patients can be long and complex, with delays that can affect outcomes. To learn more about these challenges, SPAGN’s Global Survey on Sarcoma Diagnosis Pathways is capturing real-world patient experiences from around the world. 
 
👀 Take a sneak peek at the data presented during CTOS 2024 below to learn more about the time to diagnosis and the occurence of misdiagnosis reported from 886 sarcoma patients worldwide.

All the best from the

SPAGN Board of Directors & Team

PS. The survey is still open till December 31, 2024!
If you have not done so yet, please fill it out now, every feedback counts!
🧐 What Have We Learned So Far?

Preliminary findings from over 880 patient responses across 40 countries were presented in a poster during CTOS reveal critical insights:

  • 👥 Respondent Characteristics:

    • Patients only
    • Median age: 49 years.
    • Gender: 69% female and 31% male respondents.
  • Time to Diagnosis:

    • The median time from symptom onset to a correct diagnosis exceeds 3 months across the whole patient population, with some patients waiting up to 20 years for their diagnosis.
  • 🩺 Diagnosis Intervals:

    • Patient Interval: Median time from symptom onset to the first medical visit: Median of 35 days.
    • Care Interval: Median time from the first medical visit to a correct diagnosis: Median of 60 days, with striking variation by age and sarcoma subtype.
    • The care interval consistently exceeds the patient interva
  • Rates of Misdiagnosis:

    • Misdiagnoses are prevalent with 22% across all patient groups, with the 30–44 age group reporting the highest rate at 31%.
  • 🔍 Group of 30-44 year olds:

    • Among all outcome evaluations, the 30-44 age group stands out with a median diagnostic interval of 5 months and a 31% misdiagnosis rate, higher than the overall average.
📊 Why This Survey Matters
Timely and accurate diagnoses are crucial for sarcoma patients to access effective treatments and achieve better outcomes. The current findings, along with future insights from the completed survey, will enhance our understanding of the challenges and help identify critical areas that require attention from patient advocacy groups, healthcare systems, and medical experts.
🤝 Join the Effort!
The survey remains open until December 31, 2024, and your continued participation is vital. A comprehensive analysis of the data will follow, offering actionable insights to enhance sarcoma diagnosis processes.
Follow us on our Whatsapp Channel! Join here!
X/Twitter Profile Facebook Company Name Instagram Profile YouTube channel LinkedIn company page
 
Deutsche Sarkom-Stiftung
Caspar-Bender-Weg 31
61200 Wölfersheim-Södel
Deutschland

0700-4884 0700
info@sarkome.de
www.sarkome.de
Wenn Sie diese E-Mail (an: unknown@noemail.com) nicht mehr empfangen möchten, können Sie diese hier kostenlos abbestellen.